Aims: Most biomarkers used for the premortem diagnosis of sporadic Creutzfeldt-Jakob disease (CJD) are surrogate in nature, and provide suboptimal sensitivity and specificity. Results: We report that CJD-associated brain iron dyshomeostasis is reflected in the cerebrospinal fluid (CSF), providing disease-specific diagnostic biomarkers. Analysis of 290 premortem CSF samples from confirmed cases of CJD, Alzheimer's disease, and other dementias (DMs), and 52 non-DM (ND) controls revealed a significant difference in ferroxidase (Frx) activity and transferrin (Tf) levels in sporadic Creutzfeldt-Jakob disease (sCJD) relative to other DM and ND controls. A combination of CSF Frx and Tf discriminated sCJD from other DMs with a sensitivity of 86.8%, specificity of 92.5%, accuracy of 88.9%, and area-under-the receiver-operating-characteristic (ROC) curve of 0.94. This combination provided a similar diagnostic accuracy in discriminating CJD from rapidly progressing cases who died within 6 months of sample collection. Surprisingly, ceruloplasmin and amyloid precursor protein, the major brain Frxs, displayed minimal activity in the CSF. Most of the Frx activity was concentrated in the <3-kDa fraction in normal and diseased CSF, and resisted heat and proteinase-K treatment. Innovation: (i) A combination of CSF Frx and Tf provides disease-specific premortem diagnostic biomarkers for sCJD. (ii) A novel, nonenzymatic, nonprotein Frx predominates in human CSF that is distinct from the currently known CSF Frxs. Conclusion: The underlying cause of iron imbalance is distinct in sCJD relative to other DMs associated with the brain iron imbalance. Thus, change in the CSF levels of iron-management proteins can provide disease-specific biomarkers and insight into the cause of iron imbalance in neurodegenerative conditions. Antioxid. Redox Signal. 19, 1662–1675.
BaroneE, Di DomenicoF, SultanaR, CocciaR, MancusoC, PerluigiM, ButterfieldDA. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med, 52:2292–2301. 2012.
4.
BollMC, Alcaraz-ZubeldiaM, MontesS, RiosC. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res, 33:1717–1723. 2008.
5.
BollMC, SoteloJ, OteroE, Alcaraz-ZubeldiaM, RiosC. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett, 265:155–158. 1999.
6.
BondaDJ, LeeHG, BlairJA, ZhuX, PerryG, SmithMA. Role of metal dyshomeostasis in Alzheimer's disease. Metallomics, 3:267–270. 2011.
7.
CahillCM, LahiriDK, HuangX, RogersJT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative disease. Biochim Biophys Acta, 1790:615–628. 2009.
8.
CalabreseV, SultanaR, ScapagniniG, GuaglianoE, SapienzaM, BellaR, KanskiJ, PennisiG, MancusoC, StellaAM, ButterfieldDA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal, 8:1975–1986. 2006.
9.
CapoCR, ArcielloM, SquittiR, CassettaE, RossiniPM, CalabreseL, RossiL. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals, 21:367–372. 2008.
10.
ChitravasN, JungRS, KofskeyDM, BlevinsJE, GambettiP, LeighRJ, CohenML. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol, 70:437–444. 2011.
11.
ChoHH, CahillCM, VanderburgCR, ScherzerCR, WangB, HuangX, RogersJT. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem, 285:31217–31232. 2010.
12.
ChohanG, PenningtonC, MackenzieJM, AndrewsM, EveringtonD, WillRG, KnightRS, GreenAJ. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry, 81:1243–1248. 2010.
13.
ClardySL, EarleyCJ, AllenRP, BeardJL, ConnorJR. Ferritin subunits in CSF are decreased in restless legs syndrome. J Lab Clin Med, 147:67–73. 2006.
14.
CossedduGM, NonnoR, VaccariG, BucalossiC, Fernandez-BorgesN, Di BariMA, CastillaJ, AgrimiU. Ultra-efficient PrP(Sc) amplification highlights potentialities and pitfalls of PMCA technology. PLoS Pathog, 7:e1002370. 2011.
15.
CoulthartMB, JansenGH, OlsenE, GodalDL, ConnollyT, ChoiBC, WangZ, CashmanNR. Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. BMC Neurol, 11:133. 2011.
16.
CrichtonRR, DexterDT, WardRJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm, 118:301–314. 2011.
17.
DaviesP, MouallaD, BrownDR. Alpha-synuclein is a cellular ferrireductase. PLoS One, 6:e15814. 2011.
18.
DeLongER, DeLongDM, Clarke-PearsonDL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44:837–845. 1998.
19.
Di DomenicoF, BaroneE, MancusoC, PerluigiM, CoccioloA, MecocciP, ButterfieldDA, CocciaR. HO-1/BVR-A system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease. J Alzheimers Dis, 32:277–289. 2012.
20.
DjokoKY, ChongLX, WeddAG, XiaoZ. Reaction mechanisms of the multicopper oxidase CueO from Escherichia coli support its functional role as a cuprous oxidase. J Am Chem Soc, 132:2005–2015. 2010.
21.
DoranM, LarnerAJ. EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease. Eur J Neurol, 11:838–841. 2004.
22.
DuceJA, TsatsanisA, CaterMA, JamesSA, RobbE, WikheK, LeongSL, PerezK, JohanssenT, GreenoughMA, ChoHH, GalatisD, MoirRD, MastersCL, McLeanC, TanziRE, CappaiR, BarnhamKJ, CiccotostoGD, RogersJT, BushAI. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's Disease. Cell, 142:857–867. 2010.
23.
FriedlichAL, TanziRE, RogersJT. (2007) The 5′-untranslated region of Parkinson's disease alpha-synuclein messenger RNA contains a predicted iron responsive element. Mol Psychiatry, 12:222–223. 2007.
GeschwindMD, MartindaleJ, MillerD, DeArmondSJ, Uyehara-LockJ, GaskinD, KramerJH, BarbaroNM, MillerBL. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol, 60:813–816. 2003.
GrayLW, KidaneTZ, NguyenA, AkagiS, PetrasekK, ChuYL, CabreraA, KantardjieffK, MasonAZ, LinderMC. Copper proteins and ferroxidases in human plasma and that of wild-type and ceruloplasmin knockout mice. Biochem J, 419:237–245. 2009.
29.
HaïkS, BrandelJP, SazdovitchV, Delasnerie-LauprêtreN, Peoc'hK, LaplancheJ-L, PrivatN, DuyckaertsC, KemenyJL, KoppN, LaquerrièreA, MohrM, DeslysJP, DormontD, HauwJJ. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology, 55:1401–1404. 2000.
30.
HamlinC, PuotiG, BerriS, StingE, HarrisC, CohenM, SpearC, BizziA, DebanneSM, RowlandDY. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology, 79:547–552. 2012.
Hilditch-MaguireP, TrettelF, PassaniLA, AuerbachA, PersichettiF, MacDonaldME. (2000) Huntingtin: an iron regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet, 9:2789–2797. 2000.
33.
HoltzmanDM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiology, 32:S4–S9. 2011.
34.
HwangD, LeeIY, YooH, GehlenborgN, ChoJH, PetritisB, BaxterD, PitstickR, YoungR, SpicerD, PriceND, HohmannJG, DearmondSJ, CarlsonGA, HoodLE. A systems approach to prion disease. Mol Syst Biol, 5:252. 2009.
35.
JayaratnamS, KhooAK, BasicD. Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid. Age Ageing, 37:467–469. 2008.
36.
JeongSY, DavidS. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem, 278:27144–27148. 2003.
37.
KellDB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol, 84:825–889. 2010.
38.
KhalilM, TeunissenC, LangkammerC. Iron and neurodegeneration in multiple sclerosis. Mult Scler Int, 2011:606807. 2011.
39.
LeeGR, NachtS, ChristensenD, HansenSP, CartwrightGE. The contribution of citrate to the ferroxidase activity of serum. Exp Biol Med, 131:918–923. 1969.
40.
MacKenzieEL, IwasakiK, TsujiY. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal, 10:997–1030. 2001.
41.
MattssonN, ZetterbergH, HanssonO, AndreasenN, ParnettiL, JonssonM, HerukkaSK, van der FlierWM, BlankensteinMA, EwersM, RichK, KaiserE, VerbeekM, TsolakiM, MulugetaE, RosénE, AarslandD, VisserPJ, SchröderJ, MarcussonJ, de LeonM, HampelH, ScheltensP, PirttiläT, WallinA, JönhagenME, MinthonL, WinbladB, BlennowK. CSF Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 302:385–393. 2009.
42.
MenardS. Applied Logistic Regression Analysis. Sage University Paper Series on Quantitative Applications in the Social Sciences, 07-106. Thousand Oaks, CA: Sage, 1995.
43.
MeyneF, GloecknerSF, CiesielczykB, HeinemannU, KrasnianskiA, MeissnerB, ZerrI. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis, 17:863–873. 2009.
44.
MoosT, MorganEH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci, 1012:14–26. 2004.
45.
MoosT, Rosengren NielsenT, SkjørringeT, MorganEH. Iron trafficking inside the brain. J Neurochem, 103:1730–1740. 2007.
46.
MuayqilT, GronsethG, CamicioliR. Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 79:1499–1506. 2012.
47.
NewcombeRG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med, 17:857–872. 1998.
48.
OlivieriS, ContiA, IannacconeS, CannistraciCV, CampanellaA, BarbarigaM, CodazziF, PelizzoniI, MagnaniG, PescaM, FranciottaD, CappaSF, AlessioM. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci, 31:18568–18577. 2011.
49.
OrrúCD, WilhamJM, HughsonAG, RaymondLD, McNallyKL, BossersA, LigiosC, CaugheyB. Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein. Protein Eng Des Sel, 22:515–521. 2009.
50.
PenningtonC, ChohanG, MackenzieJ, AndrewsM, WillR, KnightR, GreenA. The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. Neurosci Lett, 455:56–59. 2009.
51.
PerryDC, GeschwindMD. Thorough work-up and new diagnostic criteria needed for CJD. Nat Rev Neurol, 7:479–480. 2011.
52.
PhamAN, WaiteTD. Modeling the kinetics of Fe(II) oxidation in the presence of citrate and salicylate in aqueous solutions at pH 6.0–8.0 and 25 30)degrees C. J Phys Chem A, 112:5395–5405. 2008.
53.
PuotiG, BizziA, ForloniG, SafarJG, TagliaviniF, GambettiP. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol, 11:618–628. 2012.
SfagosC, MakisAC, ChaidosA, HatzimichaelEC, DalamagaA, KosmaK, BourantasKL. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler, 11:272–275. 2005.
56.
ShawLM, KoreckaM, ClarkCM, LeeVM, TrojanowskiJQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov, 6:295–303. 2007.
57.
SimanR, GiovannoneN, ToraskarN, FrangosS, SteinSC, LevineJM, KumarMA. Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhage. PLoS One, 6:e28938. 2011.
58.
SimelDL, SamsaGP, MatcharDB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol, 44:763–770. 1991.
59.
SinghA, BeveridgeAJ, SinghN. Decreased CSF Transferrin in sCJD: A Potential Pre-Mortem Diagnostic Test for Prion Disorders. PLoS One, 6:e16804. 2011.
60.
SinghA, IsaacAO, LuoX, MohanML, BartzJ, SinghN. Abnormal brain iron homeostasis in human and animal prion disorders. PLoS Pathog, 5:e1000336. 2009.
61.
SinghA, KongQ, LuoX, PetersenRB, MeyersonH, SinghN. Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport. PLoS One, 4:e6115. 2009.
62.
SinghA, MohanML, IsaacAO, LuoX, PetrakJ, VyoralD, SinghN. Prion protein modulates cellular iron uptake: a novel function with implications for disease pathogenesis. PLoS One, 4:e4468. 2009.
63.
SinghA, QingL, KongQ, SinghN. 2012. Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains. Neurobiol Dis, 45:930–938. 2012.
64.
SinghN, DasD, SinghA, MohanML. Prion protein and metal interaction: physiological and pathological implications. Curr Issues Mol Biol, 12:99–107. 2010.
65.
SinghN, SinghA, DasD, MohanML. Redox control of prion and disease pathogenesis. Antioxid Redox Signal, 12:1271–1294. 2010.
66.
This reference has been deleted.
67.
TaipaR, PinhoJ, Melo-PiresM. Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol, 3:68. 2012.
68.
TartagliaMC, JohnsonDY, ThaiJN, CattaruzzaT, WongK, GarciaP, DearmondSJ, MillerBL, GeschwindMD. Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease. Can J Neurol Sci, 39:304–310. 2012.
69.
ThompsonKJ, ShohamS, ConnorJR. Iron and neurodegenerative disorders. Brain Res Bull, 55:155–164. 2001.
70.
TorresM, CartierL, MatamalaJM, HernándezN, WoehlbierU, HetzC. Altered Prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease. PLoS One, 7:e36159. 2012.
71.
TschampaHJ, NeumannM, ZerrI, HenkelK, SchröterA, Schulz-SchaefferWJ, SteinhoffBJ, KretzschmarHA, PoserS. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry, 71:33–39. 2001.
72.
WattsJC, BalachandranA, WestawayD. The expanding universe of prion diseases. PLoS Pathog, 2:e26. 2006.
73.
WolozinB, GoltsN. Iron and Parkinson's disease. Neuroscientist, 8:22–32. 2002.
74.
World Health Organization. Consensus on criteria for sporadic CJD. Wkly Epidemiol Rec, 73:361–365. 1998.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
